Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection

Infection. 2002 Oct;30(5):267-71. doi: 10.1007/s15010-002-2133-y.

Abstract

Background: Bacterial and fungal infections are serious complications of cancer therapy. Especially during longstanding neutropenia, patients are at risk for life-threatening infections. The aim of this study was to assess the effect and safety of G-CSF mobilized granulocyte transfusions (GTX) in four neutropenic pediatric patients with sepsis.

Patients and methods: The patients were between 4.6-17.5 years old and their diagnoses included very severe aplastic anemia, non-Hodgkin's lymphoma (NHL) and acute myeloid leukemia. Before GTX, all patients had fever despite antibiotic and antimycotic therapy, neutropenia (absolute neutrophil count ANC < 500/microl), increasing C-reactive protein (CRP) values, hypotension requiring dopamine infusion and three patients needed supplemental oxygen. The granulocyte donors received G-CSF (Neupogen, 5 microg/kg body weight) 12 h prior to granulocyte apheresis.

Results: In total, 40 GTX were performed (range 2-28 per patient). The mean increase of the granulocyte count 1 h after GTX was 1,310/microl (range 200-2,950/microl). Within the period of GTX the CRP values decreased in all patients. During or 24 h after the last GTX, the hypotension resolved and supplemental oxygen was stopped. One GTX was discontinued because of oxygen desaturation.

Conclusion: GTX were a safe therapeutic measure with beneficial effects on serious infections in neutropenic children.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Bacteremia / complications
  • Bacteremia / diagnosis
  • Bacteremia / drug therapy
  • Child, Preschool
  • Critical Illness
  • Fatal Outcome
  • Female
  • Follow-Up Studies
  • Fungemia / complications
  • Fungemia / diagnosis
  • Fungemia / drug therapy
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Granulocyte Colony-Stimulating Factor / adverse effects
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / diagnosis
  • Hematologic Neoplasms / drug therapy*
  • Humans
  • Infusions, Intravenous
  • Male
  • Neutropenia / complications
  • Neutropenia / diagnosis
  • Neutropenia / drug therapy*
  • Risk Assessment
  • Sampling Studies
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Granulocyte Colony-Stimulating Factor